Apr 14, 2021 / NTS GMT
James Henry Barder - Futura Medical plc - CEO & Executive Director
Well, good morning, everybody, and welcome to the Futura Medical webcast for the year-end results 31st of December 2020. I'm James Barder, the Chief Executive, and I'm pleased to be joined today by Ken James, who's Executive Director and Head of R&D; and Angela Hildreth, who's Finance Director and Chief Operating Officer.
Can we please turn to the next slide? First of all, a bit of a corporate overview about Futura. We're listed on AIM. We describe ourselves as a virtual organization with 15 staff members and a number of consultants, 30 consultants. Our key asset is DermaSys. Our real expertise is in transdermal science, development of topical gels. We have a track record of clinically-proven innovation, both in sexual health and pain relief. And we have a portfolio of late-stage products with an experienced management team.
Today, we're talking about 3 of our products. Obviously, the main focus is MED3000, which is a topical gel for erectile dysfunction. Ken will also talk a little bit later on about 2 other gels
Full Year 2020 Futura Medical PLC Earnings Call Transcript
Apr 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers